Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.60 |
| ▸ | PPARG | P37231 | 7/20 | 0.57 |
| ▸ | PPARD | Q03181 | 7/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5196107 | 0.92 | CDK1 (0.64) | CDK1ADORA3ADORA1ADORA2APPARG | |
| SCHEMBL6820864 | 0.90 | CDK1 (0.76) | CDK1ADORA3ADORA1ADORA2APPARG | |
| SCHEMBL5192872 | 0.87 | CDK1 (0.79) | CDK1 | |
| SCHEMBL448405 | 0.84 | CDK1 (0.74) | CDK1ADORA3ADORA1ADORA2APPARG | |
| SCHEMBL24615063 | 0.83 | ADORA3 (0.56) | CDK1ADORA3ADORA1ADORA2APPARG | |
| SCHEMBL6820865 | 0.82 | PPARG (0.65) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL6821050 | 0.79 | CDK1 (0.79) | CDK1ADORA3ADORA1ADORA2APPARD | |
| SCHEMBL5196875 | 0.78 | CDK1 (0.83) | CDK1 | |
| SCHEMBL31072387 | 0.78 | CDK1 (0.78) | CDK1 | |
| SCHEMBL16408099 | 0.77 | ADORA3 (0.54) | ADORA3ADORA1ADORA2APPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183256-B1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2007-08-22 | — | — | EP | disclosed |
| US-7208598-B2 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7122669-B1 | Purine derivatives, preparation method and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2006-10-17 | — | — | US | disclosed |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2005-08-25 | — | — | US | disclosed |
| EP-1183256-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071543-A1 | PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | CDK6, CDK1, CDK2 | CDK1 2/4885ADORA3 320/4885ADORA1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.